Lipoprotein(a) (Lp(a)) has emerged as an important cardiovascular risk factor and is expected to become modifiable through several Lp(a)-lowering therapies in the near future. Current guidelines recommend measuring Lp(a) at least once in a lifetime, as levels are considered largely genetically determined. However...
P. Siegel, M. Gissler, M. Buechsel et al.· European Heart Journal· 0 citations
AIM OF THE STUDY
Tumor necrosis factor receptor-associated factors (TRAFs) are cytoplasmic adapter proteins that regulate immune cell signaling downstream of TNF, interleukin-1, and Toll-like receptors. Although preclinical data implicate TRAFs in atherogenesis, their clinical relevance in human disease remains unknown...
M. Gissler, Xin Gu, F. V. D. van der Zalm et al.· Atherosclerosis· 0 citations
BACKGROUND AND AIMS
While inflammation and (auto-)immunity are modifiers of atherosclerosis, immunological determinants of cardiovascular risk beyond the established inflammatory markers, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) remain incompletely defined in humans. This exploratory proof-o...
H. Horstmann, Nathaly Anto Michel, C. Losert et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.